GlaxoSmithKline PLC

36.04-0.0200-0.06%Vol 3.30M1Y Perf -7.46%
Apr 13th, 2021 16:00 DELAYED
BID35.96 ASK36.25
Open35.99 Previous Close36.06
Pre-Market- After-Market36.05
 - -  0.01 0.03%
Target Price
44.93 
Analyst Rating
Moderate Buy 2.27
Potential %
24.67 
Finscreener Ranking
★★+     47.90
Insiders Trans % 3/6/12 mo.
92/91/95 
Value Ranking
★★+     49.31
Insiders Value % 3/6/12 mo.
-40/60/62 
Growth Ranking
★★★     53.64
Insiders Shares Cnt. % 3/6/12 mo.
-40/61/63 
Income Ranking
★★     39.49
Market Cap97.04B 
Earnings Rating
Strong Sell
Price Range Ratio 52W %
28.02 
Earnings Date
5th May 2021

Today's Price Range

35.8436.19

52W Range

33.2643.18

5 Year PE Ratio Range

7.3097.00

Summary:

Sell

Technical Indicators: Neutral
Moving Averages: Strong Sell
Performance
1 Week
-0.06%
1 Month
1.41%
3 Months
-5.56%
6 Months
-1.92%
1 Year
-7.46%
3 Years
-11.19%
5 Years
-13.42%
10 Years
13.18%

TickerPriceChg.Chg.%
GSK36.04-0.0200-0.06
AAPL134.433.19002.43
GOOG2 267.2712.48000.55
MSFT258.312.40000.94
XOM55.710.21000.38
WFC39.79-0.9800-2.40
JNJ159.48-2.1600-1.34
FB309.76-1.7800-0.57
GE13.44-0.1500-1.10
JPM154.09-1.8600-1.19
Financial StrengthValueIndustryS&P 500US Markets
0.30
0.90
0.62
1.86
9.10
Leverage Ratio 5.90
ProfitabilityValueIndustryS&P 500US Markets
65.70
22.90
29.80
12.40
18.83
RevenueValueIndustryS&P 500US Markets
30.81B
12.25
4.84
6.61
DividendsValueIndustryS&P 500US Markets
7.06
2.55
-0.91
-2.39
Payout ratio62.00
Earnings HistoryEstimateReportedSurprise %
Q04 20200.700.62-11.43
Q03 20200.780.9217.95
Q02 20200.490.48-2.04
Q01 20200.790.9722.78
Q04 20190.680.64-5.88
Q03 20190.830.9514.46
Q02 20190.640.7821.88
Q01 20190.660.7919.70
Earnings Per EndEstimateRevision %Trend
3/2021 QR0.69-16.87Negative
6/2021 QR0.57-5.00Negative
12/2021 FY2.78-9.74Negative
12/2022 FY3.02-3.82Negative
Next Report Date5th May 2021
Estimated EPS Next Report0.69
Estimates Count3
EPS Growth Next 5 Years %3.90
Volume Overview
Volume3.30M
Shares Outstanding2.69B
Trades Count21.12K
Dollar Volume223.29M
Avg. Volume5.91M
Avg. Weekly Volume4.38M
Avg. Monthly Volume4.99M
Avg. Quarterly Volume6.12M

GlaxoSmithKline PLC (NYSE: GSK) stock closed at 36.04 per share at the end of the most recent trading day (a -0.06% change compared to the prior day closing price) with a volume of 3.30M shares and market capitalization of 97.04B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 99437 people. GlaxoSmithKline PLC CEO is Emma N. Walmsley.

The one-year performance of GlaxoSmithKline PLC stock is -7.46%, while year-to-date (YTD) performance is -2.07%. GSK stock has a five-year performance of -13.42%. Its 52-week range is between 33.26 and 43.18, which gives GSK stock a 52-week price range ratio of 28.02%

GlaxoSmithKline PLC currently has a PE ratio of 12.00, a price-to-book (PB) ratio of 4.55, a price-to-sale (PS) ratio of 2.94, a price to cashflow ratio of 7.90, a PEG ratio of 2.32, a ROA of 7.00%, a ROC of 16.30% and a ROE of 43.23%. The company’s profit margin is 18.83%, its EBITDA margin is 29.80%, and its revenue ttm is $30.81 Billion , which makes it $12.25 revenue per share.

Of the last four earnings reports from GlaxoSmithKline PLC, there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $0.69 for the next earnings report. GlaxoSmithKline PLC’s next earnings report date is 05th May 2021.

The consensus rating of Wall Street analysts for GlaxoSmithKline PLC is Moderate Buy (2.27), with a target price of $44.93, which is +24.67% compared to the current price. The earnings rating for GlaxoSmithKline PLC stock is Strong Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

GlaxoSmithKline PLC has a dividend yield of 7.06% with a dividend per share of $2.55 and a payout ratio of 62.00%.

GlaxoSmithKline PLC has a Sell technical analysis rating based on Technical Indicators (ADX : 7.08, ATR14 : 0.74, CCI20 : -55.62, Chaikin Money Flow : 0.08, MACD : -0.24, Money Flow Index : 52.92, ROC : -0.08, RSI : 42.78, STOCH (14,3) : 41.54, STOCH RSI : 0.40, UO : 51.09, Williams %R : -58.46), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of GlaxoSmithKline PLC in the last 12-months were: Charles A. Bancroft (Buy at a value of $153 095), Emma N. Walmsley (Buy at a value of $2 258), Emma N. Walmsley (Sold 32 346 shares of value $391 613 ), Hal V Barron (Buy at a value of $11 789 953), Hal V Barron (Sold 173 710 shares of value $3 100 532 ), Jesse Goodman (Buy at a value of $133 973), Jonathan Richard Symonds (Buy at a value of $700 868), Jonathan Richard Symonds (Sold 17 888 shares of value $235 567 ), Judy C. Lewent (Buy at a value of $141 205), Laurie H. Glimcher (Buy at a value of $420 150), Lynn Laverty Elsenhans (Buy at a value of $236 050), Manvinder Singh Banga (Buy at a value of $601 548), Urs Rohner (Buy at a value of $81 557), Vivienne Cox (Buy at a value of $81 524)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (45.45 %)
5 (45.45 %)
5 (45.45 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
5 (45.45 %)
5 (45.45 %)
5 (45.45 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (9.09 %)
1 (9.09 %)
1 (9.09 %)
Summary RatingModerate Buy
2.27
Moderate Buy
2.27
Moderate Buy
2.27

GlaxoSmithKline PLC

In the pharmaceutical industry, GlaxoSmithKline ranks as one of the largest companies by total sales. The company wields its might across several therapeutic classes, including respiratory, oncology, and antiviral, as well as vaccines and consumer healthcare products. Glaxo uses joint ventures to gain additional scale in certain markets like HIV and consumer products.

CEO: Emma N. Walmsley

Telephone: +44 2080475000

Address: 980 Great West Road, Brentford TW8 9GS, Middlesex, GB

Number of employees: 99 437

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

53%47%

Bearish Bullish

56%44%

Bearish Bullish

55%45%

News

Stocktwits